Stockreport

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

Oncolytics Biotech Inc. - Common Shares  (ONCY) 
Last oncolytics biotech inc. - common shares earnings: 11/12 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.oncolyticsbiotech.com
PDF Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancerOverall survival results from the rando [Read more]